Propanc Biopharma Receives Acceptance of Key Patent Application for Cancer Treatment in China

Source: http://ift.tt/UTGs1Q --- Thursday, July 20, 2017
Patent covers use of a pharmaceutical composition comprising trypsinogen and chymotrypsinogen MELBOURNE, Australia--(Marketwired - July 20, 2017) - Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that it received notification of acceptance for its lead patent application from the Chinese Patent Office. The patent application provides broad coverage of a pharmaceutical composition of trypsinogen and chymotrypsinogen to treat certain cancers.The acceptance of this key patent application is a first in China, representing yet another significant milestone for the Company, as it progresses its lead product, PRP, towards First-In-Human studies. Given that China accounts for more than 20% of the world's population, significant growth in this pharmaceutical market is anticipated due to greater healthcare coverage for a rising middle class. The Company is considering filing a divisional application with the Chinese Patent Office to pursue additional claims based off the initial accepted application."Acceptance of our first Chinese patent is a significant achievement for our Company, and indicates the strong growth of intellectual property portfolio worldwide," said James Nathanielsz, Propanc Biop ...

from Australia http://ift.tt/2udzd82